Investigating a new therapy for chronic kidney disease using a protein called ANGPTL4
Recombinant hANGPTL4 and CKD
['FUNDING_R01'] · RUSH UNIVERSITY MEDICAL CENTER · NIH-10993136
This study is looking at a special protein called ANGPTL4 to see if it can help people with chronic kidney disease by reducing protein in their urine and protecting their kidneys, especially for those who haven't found relief with current treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUSH UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10993136 on ClinicalTrials.gov |
What this research studies
This research focuses on the potential of a protein known as Angiopoietin-like 4 (ANGPTL4) to reduce proteinuria and slow the progression of chronic kidney disease (CKD). The study involves testing mutated versions of ANGPTL4 in rat models of diabetic nephropathy and focal segmental glomerulosclerosis to assess their effectiveness in preserving kidney function and reducing kidney damage. By examining how ANGPTL4 interacts with kidney cells, the researchers aim to uncover new therapeutic strategies for patients with CKD who are not responding well to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic kidney disease, particularly those with diabetic nephropathy or focal segmental glomerulosclerosis.
Not a fit: Patients with acute kidney injury or those whose CKD is not related to diabetes or glomerulosclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly slows the progression of chronic kidney disease and improves kidney function in affected patients.
How similar studies have performed: Previous studies have shown promising results with similar approaches using ANGPTL4 in animal models, indicating potential for success in human applications.
Where this research is happening
CHICAGO, UNITED STATES
- RUSH UNIVERSITY MEDICAL CENTER — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHUGH, SUMANT SINGH — RUSH UNIVERSITY MEDICAL CENTER
- Study coordinator: CHUGH, SUMANT SINGH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: adult onset diabetes, Adult-Onset Diabetes Mellitus